RxDoctor Payments Data

Jody Ardrey

Family · Ada, OKNPI 1881902377

Payments from drug & device makers

$442in general payments, 2019–2025

Across 28 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$114
  • Novo Nordisk$80
  • Pfizer$74
  • Sanofi-aventis U.S. LLC$45
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30
  • Lundbeck LLC$24
  • plus $76 from 5 others

What the payments were for

  • Food & beverage$442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$442 in reported general payments places this provider in the 50th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$6,783
Medicare patients
308
Services billed
1,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$233,360
OzempicSemaglutide145$208,156
FarxigaDapagliflozin Propanediol134$202,713
MounjaroTirzepatide66$77,995
VraylarCariprazine Hcl27$72,931
XeljanzTofacitinib Citrate12$62,911
Tresiba Flextouch U-200Insulin Degludec45$59,668
XareltoRivaroxaban40$56,942
MyrbetriqMirabegron54$40,171
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$38,609
JanuviaSitagliptin Phosphate21$34,524
LinzessLinaclotide29$32,896
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$29,901
TrulicityDulaglutide18$23,077
Tresiba Flextouch U-100Insulin Degludec33$22,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Xeljanz$74$296,271188 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$114$237,803172 claims
Novo NordiskOzempic$80$208,156145 claims
AbbVieVraylar, Linzess$13$105,82756 claims
MerckJanuvia$13$34,52421 claims
Sumitomo Pharma America, Inc.Gemtesa$20$14,84011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,026 family providers in Oklahoma.

Other family in Ada

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →